Kim A Papp (Kim Parnell, K A Papp, Kim Papp, K Papp)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 93

Top Topics

Atopic Dermatitis

Top Venues

The British journal of dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

Dermatology and therapy

Rheumatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Erika Yue Lee, Irina Turchin, An-Wen Chan, Jennifer Beecker, Robert Bissonnette, Helen Catherall, Amanda Cresswell-Melville, Melinda Gooderham, Nicole Hawkins, H Chih-Ho Hong, Nick J Levell, Jo-Ann Lapointe McKenzie, Rachael Manion, Kim A Papp, Aaron M Drucker
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey. Journal of cutaneous medicine and surgery (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Kim A Papp, S Beyska-Rizova, M L Gantcheva, E Slavcheva Simeonova, P Brezoev, M Celic, L Groppa, T Blicharski, A Selmanagic, M Kalicka-Dudzik, C A Calin, N Trailovic, M Ramon, A Bareket-Samish, Z Harpaz, M Farbstein, M H Silverman, Pnina Fishman, null null
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Robert Bissonnette, Andreas Pinter, Laura K Ferris, Sascha Gerdes, Phoebe Rich, Ronald Vender, Megan Miller, Yaung-Kaung Shen, Arun Kannan, Shu Li, Cynthia DeKlotz, Kim A Papp
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. The New England journal of medicine 390 (6) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy (2024)
Mark G Kirchhof, Vimal H Prajapati, Melinda J Gooderham, H Chih-Ho Hong, Charles W Lynde, Catherine Maari, Irina Turchin, Kim A Papp
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors. Dermatology and therapy (2024)
H Bachelez, Christopher Ernest Maitland Griffiths, Kim A Papp, S Hall, Joseph Frank Merola, Steven Richard Feldman, M Khraishi, H Tan, L Fallon, J C Cappelleri, A G Bushmakin, P Young
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Robert Bissonnette, Andreas Pinter, Laura K Ferris, Sascha Gerdes, Phoebe Rich, Ronald Vender, Megan Miller, Yaung-Kaung Shen, Arun Kannan, Shu Li, Cynthia DeKlotz, Kim A Papp
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. The New England journal of medicine 390 (6) (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy (2024)
H Bachelez, Christopher Ernest Maitland Griffiths, Kim A Papp, S Hall, Joseph Frank Merola, Steven Richard Feldman, M Khraishi, H Tan, L Fallon, J C Cappelleri, A G Bushmakin, P Young
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (7) (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Stephen Tyring, Angela Moore, Akimchi Morita, H Chih-Ho Hong, In-Ho Song, Jason Eccleston, Gweneth Levy, Mohamed-Eslam F Mohamed, Yuli Qian, Tianshuang Wu, Anqi Pan, Kinjal Hew, Kim A Papp
Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial. Clinical and experimental dermatology (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Kim A Papp, S Beyska-Rizova, M L Gantcheva, E Slavcheva Simeonova, P Brezoev, M Celic, L Groppa, T Blicharski, A Selmanagic, M Kalicka-Dudzik, C A Calin, N Trailovic, M Ramon, A Bareket-Samish, Z Harpaz, M Farbstein, M H Silverman, Pnina Fishman, null null
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (6) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Vimal H Prajapati, Charles W Lynde, Melinda J Gooderham, H Chih-Ho Hong, Mark G Kirchhof, Perla Lansang, Julien Ringuet, Irina Turchin, Ronald B Vender, Jensen Yeung, Kim A Papp
Considerations for defining and diagnosing generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
H Bachelez, Christopher Ernest Maitland Griffiths, Kim A Papp, S Hall, Joseph Frank Merola, Steven Richard Feldman, M Khraishi, H Tan, L Fallon, J C Cappelleri, A G Bushmakin, P Young
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (7) (2024)
Kim A Papp, S Beyska-Rizova, M L Gantcheva, E Slavcheva Simeonova, P Brezoev, M Celic, L Groppa, T Blicharski, A Selmanagic, M Kalicka-Dudzik, C A Calin, N Trailovic, M Ramon, A Bareket-Samish, Z Harpaz, M Farbstein, M H Silverman, Pnina Fishman, null null
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (6) (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A Papp
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO). The Journal of dermatological treatment 35 (1) (2024)
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Zoe D Draelos, Janet DuBois, Melinda J Gooderham, Steven E Kempers, Edward Lain, Mark Lee, Angela Moore, Dedee Frances Murrell, Kim A Papp, David M Pariser, Rodney Sinclair, Matthew Zirwas, Patrick Burnett, Robert C Higham, David Krupa, David R Berk
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase 2b study. The British journal of dermatology (2023)
Kim A Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J Hotte, Jennifer R Beecker, Mark G Kirchhof, Irina Turchin, Jan P Dutz, Melinda J Gooderham, Robert Gniadecki, Chih-Ho Hong, Jo Lambert, Charles W Lynde, Vimal H Prajapati, Ronald B Vender
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and therapy (2023)
Linda F Stein Gold, Jerry Bagel, Stephen Keith Tyring, H Chih-Ho Hong, Lev Pavlovsky, Ronald B Vender, Andreas Pinter, Adam Reich, Leonidas Drogaris, Tianshuang Wu, Manish Patel, Ahmed M Soliman, Huzefa Photowala, Vassilis Stakias, Sven Richter, Kim A Papp
Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study. The British journal of dermatology (2023)
Kim A Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J Hotte, Jennifer R Beecker, Mark G Kirchhof, Irina Turchin, Jan P Dutz, Melinda J Gooderham, Robert Gniadecki, Chih-Ho Hong, Jo Lambert, Charles W Lynde, Vimal H Prajapati, Ronald B Vender
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and therapy (2023)
Kim A Papp, Jennifer Beecker, Curtis L Cooper, Mark G Kirchhof, Anton L Pozniak, Juergen K Rockstroh, Jan P Dutz, Melinda J Gooderham, Robert Gniadecki, H Chih-Ho Hong, Charles W Lynde, Catherine Maari, Yves Poulin, Ronald B Vender, Sharon L Walmsley
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and therapy (2023)
Alexa B Kimball, Maurizio Podda, Afsaneh Alavi, Megan Miller, Yaung-Kaung Shen, Shu Li, Yan Xu, Chenglong Han, Steven Fakharzadeh, Ya-Wen Yang, Samuel DePrimo, Ernesto Munoz, Yanqing Chen, Thierry Passeron, Kim A Papp
Guselkumab for the Treatment of Patients with Moderate-to-severe Hidradenitis Suppurativa: A Phase 2 Randomized Study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Emma Guttman-Yassky, Jonathan Ian Silverberg, Diamant Thaçi, Kim A Papp, Sonja Ständer, Lisa A Beck, Brian S Kim, Xiaofei Hu, Jianzhong Liu, Brian M Calimlim, Namita Vigna, Jameson T Crowley, Henrique D Teixeira, Jacob Pontoppidan Thyssen
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
D N Adam, M J Gooderham, J R Beecker, C H Hong, C S Jack, V Jain, P Lansang, C W Lynde, Kim A Papp, V H Prajapati, I Turchin, J Yeung
Expert Consensus on the Systemic Treatment of Atopic Dermatitis in Special Populations. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
D N Adam, M J Gooderham, J R Beecker, C H Hong, C S Jack, V Jain, P Lansang, C W Lynde, Kim A Papp, V H Prajapati, I Turchin, J Yeung
Expert consensus on the systemic treatment of atopic dermatitis in special populations. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kim A Papp, Mark G Lebwohl, Diamant Thaҫi, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek Cezary Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Andrew Blauvelt, Diamant Thaҫi, Kim A Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G Lebwohl, Alice B Gottlieb, Jeffrey Crowley, Peter Foley
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. The British journal of dermatology (2023)
Lawrence F Eichenfield, Linda Stein Gold, Leon H Kircik, William P Werschler, Kenneth Beer, Zoe D Draelos, Emil A Tanghetti, Kim A Papp, Hilary Baldwin, Edward Lain, Neil Sadick, Melinda J Gooderham, Adarsh Konda
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study. Pediatric dermatology (2023)
K Reich, Jonathan Ian Silverberg, Kim A Papp, Mette Deleuran, N Katoh, Bruce E Strober, Lisa A Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D DiBonaventura, G Chan, S Johnson, S A Farooqui, U Kerkmann, C Clibborn
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Zoe D Draelos, David N Adam, Chih Ho Hong, Mark G Lebwohl, Charles W Lynde, Walter K Nahm, Kim A Papp, David M Pariser, Linda Stein Gold, Daniel Stewart, Robert C Higham, David R Berk, David Krupa, Patrick Burnett
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. The British journal of dermatology (2023)
K Reich, Jonathan Ian Silverberg, Kim A Papp, Mette Deleuran, N Katoh, Bruce E Strober, Lisa A Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D DiBonaventura, G Chan, S A Farooqui, U Kerkmann, C Clibborn
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, Kim A Papp, Lyn C Guenther, Wayne P Gulliver, Vincent Ho, Neil H Shear, Ronald B Vender, Robert Gniadecki, Vimal H Prajapati, Irina Turchin, Wayne Langholff, Kim A Papp, Scott D Simpson, Nastaran Abbarin, Omair Lakhani, Raed Alhusayen
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of cutaneous medicine and surgery (2023)
L E Kristensen, A M Soliman, Kim A Papp, Joseph Frank Merola, L Barcomb, Z Wang, A Eldred, F Behrens
Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (5) (2022)
Jonathan Ian Silverberg, Mark Boguniewicz, Jon Hanifin, Kim A Papp, Haixin Zhang, Ana Beatris Rossi, Noah A Levit
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials. Dermatology and therapy 12 (12) (2022)
Andrew Blauvelt, Leon Kircik, Kim A Papp, Eric L Simpson, Jonathan Ian Silverberg, Brian S Kim, Shawn G Kwatra, Michael E Kuligowski, May E Venturanza, Shaoceng Wei, Jacek Cezary Szepietowski
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
L E Kristensen, A M Soliman, Kim A Papp, L Barcomb, A Eldred, A Östör
The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (11) (2022)
Kim A Papp, Jennifer Beecker, Curtis L Cooper, Mark G Kirchhof, Anton L Pozniak, Juergen K Rockstroh, Jan P Dutz, Melinda J Gooderham, Robert Gniadecki, H Chih-Ho Hong, Charles W Lynde, Catherine Maari, Yves Poulin, Ronald B Vender, Sharon L Walmsley
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and therapy 12 (5) (2022)
Eric L Simpson, Joseph Frank Merola, Jonathan Ian Silverberg, Kristian Reich, Richard B Warren, Delphine Staumont-Sallé, Giampiero Girolomoni, Kim A Papp, Marjolein de Bruin-Weller, Jacob P Thyssen, Rebecca Zachariae, Christiana K Olsen, Andreas Wollenberg
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. The British journal of dermatology 187 (6) (2022)
Gil Yosipovitch, Kim A Papp, Seth Forman, George Han, Jill Waibel, Maria J Rueda, Luna Sun, Yun-Fei Chen, Orin Goldblum, Evangeline Pierce, Jonathan Ian Silverberg
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. The British journal of dermatology 186 (6) (2022)
Mark G Lebwohl, Linda Stein Gold, Bruce Strober, Kim A Papp, April W Armstrong, Jerry Bagel, Leon Kircik, Benjamin Ehst, H Chih-Ho Hong, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen C Piscitelli, David S Rubenstein, Philip M Brown, Anna M Tallman, Robert Bissonnette
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. The New England journal of medicine 385 (24) (2021)
Kim A Papp, Saskia de Vente, Jiewei Zeng, Mary Flack, Byron Padilla, Stephen K Tyring
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. Dermatology and therapy 11 (2) (2021)
Kim A Papp, M G Lebwohl, Lluis L Puig, M Ohtsuki, S Beissert, J Zeng, S Rubant, R Sinvhal, Y Zhao, A M Soliman, G Alperovich, C Leonardi
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. The British journal of dermatology (2021)
Baldwin C Mak, Bryan T Addeman, Jia Chen, Kim A Papp, Melinda J Gooderham, Lyn C Guenther, Yi Liu, Uli C Broedl, Marianne E Logger
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot. Blockchain in healthcare today 4 (2021)
Kim A Papp, Gurbir Dhadwal, Melinda Gooderham, Lyn Guenther, Irina Turchin, Marni Wiseman, Jensen Yeung
Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. Dermatologic therapy 34 (6) (2021)
Kim A Papp, Melinda J Gooderham, Charles W Lynde, Yves Poulin, Jennifer Beecker, Jan P Dutz, Chih-Ho Hong, Robert Gniadecki, Mark G Kirchhof, Catherine Maari, Ronald B Vender
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and therapy 12 (1) (2021)
Abby S Van Voorhees, L Stein Gold, M Lebwohl, Bruce E Strober, Howard Sofen, Kim A Papp, J Bagel, Z Zhang, M Paris, Y Wang
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. The British journal of dermatology 185 (4) (2021)
Baldwin C Mak, Bryan T Addeman, Jia Chen, Kim A Papp, Melinda J Gooderham, Lyn C Guenther, Yi Liu, Uli C Broedl, Marianne E Logger
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot. Blockchain in healthcare today 4 (2021)
W Gulliver, A Alavi, M C Wiseman, M J Gooderham, J Rao, M S Alam, Kim A Papp, O Desjardins, C Jean
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (12) (2021)
Mark G Lebwohl, Linda F Stein Gold, Kim A Papp, G Han, D M Pariser, T Lin, S Harris, A Jacobson
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (5) (2021)
Kim A Papp, Robert Gniadecki, Jennifer Beecker, Jan Dutz, Melinda J Gooderham, Chih-Ho Hong, Mark G Kirchhof, Chuck W Lynde, Catherine Maari, Yves Poulin, Ronald B Vender
Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and therapy 11 (3) (2021)
Kenneth B Gordon, M Lebwohl, Kim A Papp, H Bachelez, J J Wu, R G Langley, Andrew Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, Kristian Reich
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. The British journal of dermatology (2021)
Jennifer Beecker, Kim A Papp, J Dutz, Ronald B Vender, Robert Gniadecki, Curtis L Cooper, Paolo Gisondi, Melinda J Gooderham, C H Hong, M G Kirchhof, C W Lynde, C Maari, Y Poulin, Lluis L Puig
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (4) (2021)
Kim A Papp, Melinda J Gooderham, L E Albrecht, M-A Raymond, C W Lynde
Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting. The British journal of dermatology (2021)
Kim A Papp, Chih-Ho Hong, M Perla Lansang, Irina Turchin, David N Adam, Jennifer R Beecker, Robert Bissonnette, Melinda J Gooderham, Carolyn Jack, Marissa Joseph, Charles W Lynde, Neil H Shear
Practical Management of Patients with Atopic Dermatitis on Dupilumab. Dermatology and therapy 11 (5) (2021)
Kim A Papp, Ahmed M Soliman, Nicolae Done, Christopher Carley, Esteban Lemus Wirtz, Luis Puig
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and therapy 11 (4) (2021)
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi, Luke Peterson, Nancy Cross, Kristian Reich
Bimekizumab versus Adalimumab in Plaque Psoriasis. The New England journal of medicine 385 (2) (2021)
Amy S Paller, M M B Seyger, G Alejandro Magariños, J Bagel, Andreas Pinter, J Cather, S Keller, C Rodriguez Capriles, R Gontijo Lima, G Gallo, C A Little, Emily Edson-Heredia, L Li, W Xu, Kim A Papp, null null
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). The British journal of dermatology 183 (2) (2020)
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn C Guenther, Melinda J Gooderham, Laura K Ferris, Christopher E M Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim A Papp
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and therapy 10 (3) (2020)
Kristian Reich, Kim A Papp, April W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, Alexa B Kimball
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. The British journal of dermatology 180 (5) (2020)
Andrew Blauvelt, C Leonardi, Boni E Elewski, J J Crowley, L C Guenther, Melinda J Gooderham, R G Langley, Ronald B Vender, Andreas Pinter, C E M Griffiths, Y Tada, H Elmaraghy, R G Lima, G Gallo, L Renda, Russel T Burge, S Y Park, B Zhu, Kim A Papp, null null
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. The British journal of dermatology 184 (6) (2020)
Mark G Lebwohl, Kim A Papp, Linda Stein Gold, Melinda J Gooderham, Leon H Kircik, Zoe D Draelos, Steven E Kempers, Mathew Zirwas, Kathleen Smith, David W Osborne, Marie-Louise Trotman, Lynn Navale, Charlotte Merritt, David R Berk, Howard Welgus, null null
Trial of Roflumilast Cream for Chronic Plaque Psoriasis. The New England journal of medicine 383 (3) (2020)
Mark G Lebwohl, Andrew Blauvelt, Martin Alan Menter, Kim A Papp, Scott Guenthner, Radhakrishnan Pillai, Robert J Israel, Abby Jacobson
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American journal of clinical dermatology 20 (6) (2020)
Novin Nezamololama, Erika L Crowley, Melinda J Gooderham, Kim A Papp
Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert opinion on investigational drugs 29 (9) (2020)
Andrew Blauvelt, Kim A Papp, A Gottlieb, A Jarell, Kristian Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada, R G Lima, H Elmaraghy, G Gallo, L Renda, S Y Park, R Burge, J Bagel, null null
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. The British journal of dermatology 182 (6) (2020)
Christopher Ernest Maitland Griffiths, Kim A Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, Andrew Blauvelt
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. The Journal of dermatological treatment (2020)
Kim A Papp, A Menter, C Leonardi, J Soung, S Weiss, R Pillai, A Jacobson
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). The British journal of dermatology 183 (6) (2020)
Alexa B Kimball, T Kerbusch, F van Aarle, P Kulkarni, Q Li, Andrew Blauvelt, Kim A Papp, Kristian Reich, D Montgomery
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. The British journal of dermatology 182 (1) (2019)
J Hercogová, Kim A Papp, V Chyrok, M Ullmann, P Vlachos, C J Edwards
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. The British journal of dermatology 182 (2) (2019)
K Reich, P Rich, C Maari, Robert Bissonnette, C Leonardi, A Menter, A Igarashi, P Klekotka, D Patel, J Li, J Tuttle, M Morgan-Cox, Emily Edson-Heredia, S Friedrich, Kim A Papp, null null
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. The British journal of dermatology 181 (1) (2019)
April W Armstrong, Kristian Reich, Peter Foley, Chenglong Han, Michael Song, Yaung-Kaung Shen, Yin You, Kim A Papp
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. American journal of clinical dermatology 20 (1) (2019)
D Thaçi, Kim A Papp, D Marcoux, L Weibel, A Pinter, P-D Ghislain, I Landells, Peter H Hoeger, K Unnebrink, M M B Seyger, D A Williams, S Rubant, S Philipp
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. The British journal of dermatology 181 (6) (2019)
A B Gottlieb, A Kubanov, M van Doorn, J Sullivan, Kim A Papp, R You, P Regnault, J A Frueh
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. The British journal of dermatology 182 (4) (2019)
A B Kimball, Kim A Papp, K Reich, Melinda J Gooderham, Q Li, N Cichanowitz, C La Rosa, Andrew Blauvelt
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. The British journal of dermatology 182 (6) (2019)
Kim A Papp, C Maari, A Cauthen, Melinda J Gooderham, Lynda Spelman, Keiichi Yamanaka, P Polzer, L Zhang, O Osuntokun, Matthias Augustin
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. The British journal of dermatology 183 (1) (2019)
Kim A Papp, K B Gordon, R G Langley, M G Lebwohl, A B Gottlieb, S Rastogi, R Pillai, R J Israel
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. The British journal of dermatology 179 (2) (2018)
Mysore S Anil Kumar, Kim A Papp, Ryo Tainaka, Udaya Valluri, Xuegong Wang, Tong Zhu, Christian Schwabe
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. Biopharmaceutics & drug disposition 39 (5) (2018)
C Leonardi, Kim A Papp, Bruce E Strober, D Thaçi, R B Warren, S Tyring, D Arikan, M Karunaratne, W C Valdecantos
Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. The British journal of dermatology 180 (1) (2018)
Kim A Papp, Kenneth Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G Girgis, Sudeep Kundu, Subhashis Banerjee
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. The New England journal of medicine 379 (14) (2018)
Andrew Blauvelt, Kristian Reich, Kim A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaçi, Q Li, N Cichanowitz, S Green, C La Rosa
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. The British journal of dermatology 179 (3) (2018)
Kim A Papp, C L Leonardi, Andrew Blauvelt, Kristian Reich, N J Korman, M Ohtsuki, Carle F Paul, S Ball, G S Cameron, J Erickson, L Zhang, L Mallbris, C E M Griffiths
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). The British journal of dermatology 178 (3) (2018)
R G Langley, Kim A Papp, M Gooderham, L Zhang, C Mallinckrodt, N Agada, Andrew Blauvelt, P Foley, P Polzer, null null
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). The British journal of dermatology 178 (6) (2018)
Kim A Papp, M Gooderham, R Jenkins, R Vender, J C Szepietowski, T Wagner, B Hunt, B Souberbielle, null null
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. The British journal of dermatology 180 (6) (2018)
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, Kim A Papp
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. The British journal of dermatology 177 (2) (2017)